Journal
IMMUNOTHERAPY
Volume 7, Issue 12, Pages 1259-1271Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt.15.91
Keywords
bladder cancer; checkpoint inhibitors; CTLA4; immunotherapy; PD1/PDL1; renal cell carcinoma
Categories
Ask authors/readers for more resources
The field of immunotherapy in urinary malignancy is expanding in several directions and checkpoint inhibitors are leading the way. The aim of this report is to highlight the efficacy and safety profile of the two classes of molecules, anti-cytotoxic T-lymphocyte antigen-4 and anti-programmed death receptor-1/programmed death ligand type 1, that are under investigation and represent potential candidates to be used in the near future for the management of bladder and renal cell cancer. The preliminary results as well as the future perspectives of this novel immunotherapy are analyzed. Novel immune checkpoint targets are reviewed as well.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available